Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk

被引:38
作者
Blanco-Colio, Luis M. [1 ]
Martin-Ventura, Jose L. [1 ]
Gomez-Guerrero, Cannen [1 ]
Masramon, Xavier [2 ]
de Teresa, Eduardo [3 ,4 ]
Farsang, Csaba [5 ]
Gaw, Allan [6 ]
Gensini, GianFranco [7 ]
Leiter, Lawrence A. [8 ,9 ]
Langer, Anatoly [8 ,9 ,10 ]
Egido, Jesus [1 ]
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Vasc Res Lab, E-28040 Madrid, Spain
[2] European Biometr Inst, Barcelona, Spain
[3] Univ Malaga, E-29071 Malaga, Spain
[4] Victoria Hosp, Malaga, Spain
[5] Semmelweis Univ, Dept Med 1, H-1085 Budapest, Hungary
[6] Univ Glasgow, Glasgow, Lanark, Scotland
[7] Univ Florence, Careggi Hosp, Florence, Italy
[8] Univ Toronto, Toronto, ON, Canada
[9] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[10] Canadian Heart Res Ctr, Toronto, ON, Canada
关键词
cholesterol-lowering drugs; high cardiovascular risk; inflammation; adiponectin;
D O I
10.1016/j.ejphar.2008.02.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N=40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95% CI); P < 0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);% Change (95% CI); P=0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P=0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:259 / 265
页数:7
相关论文
共 39 条
  • [1] Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes
    Ahn, Jiyun
    Lee, Hyunjung
    Kim, Suna
    Ha, Taeyoul
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 364 (04) : 972 - 977
  • [2] Effect of adiponectin on carotid arterial stiffness in type 2 diabetic patients treated with pioglitazone and metformin
    Araki, Takahiro
    Emoto, Masanori
    Teramura, Megumi
    Yokoyama, Hisayo
    Mori, Katsuhito
    Hatsuda, Sawako
    Maeno, Takaaki
    Shinohara, Kayo
    Koyama, Hidenori
    Shoji, Tetsuo
    Inaba, Masaaki
    Nishizawa, Yoshiki
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2006, 55 (08): : 996 - 1001
  • [3] Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell
    Arita, Y
    Kihara, S
    Ouchi, N
    Maeda, K
    Kuriyama, H
    Okamoto, Y
    Kumada, M
    Hotta, K
    Nishida, M
    Takahashi, M
    Nakamura, T
    Shimomura, I
    Muraguchi, M
    Ohmoto, Y
    Funahashi, T
    Matsuzawa, Y
    [J]. CIRCULATION, 2002, 105 (24) : 2893 - 2898
  • [4] Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients
    Ascer, E
    Bertolami, MC
    Venturinelli, ML
    Buccheri, V
    Souza, J
    Nicolau, JC
    Ramires, JAF
    Serrano, CV
    [J]. ATHEROSCLEROSIS, 2004, 177 (01) : 161 - 166
  • [5] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    Baigent, C
    Keech, A
    Kearney, PM
    Blackwell, L
    Buck, G
    Pollicino, C
    Kirby, A
    Sourjina, T
    Peto, R
    Collins, R
    Simes, J
    [J]. LANCET, 2005, 366 (9493) : 1267 - 1278
  • [6] Effect of atorvastatin on soluble CD14, CD40 ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus:: Relationship to cholesterol turnover
    Blaha, Vladimir
    Andrys, Ctirad
    Smahelova, Alena
    Knizek, Jiri
    Hyspler, Radomir
    Solichova, Dagmar
    Blaha, Milan
    Zadak, Zdenek
    [J]. PHARMACOLOGICAL RESEARCH, 2006, 54 (06) : 421 - 428
  • [7] Adiponectin stimulates production of nitric oxide in vascular endothelial cells
    Chen, H
    Montagnani, M
    Funahashi, T
    Shimomura, I
    Quon, MJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) : 45021 - 45026
  • [8] Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
    Chu, CS
    Lee, KT
    Lee, MY
    Su, HM
    Voon, WC
    Sheu, SH
    Lai, WT
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (05) : 646 - 650
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome
    Esposito, K
    Ciotola, M
    Carleo, D
    Schisano, B
    Saccomanno, F
    Sasso, FC
    Cozzolino, D
    Assaloni, R
    Merante, D
    Ceriello, A
    Giugliano, D
    [J]. DIABETES CARE, 2006, 29 (05) : 1071 - 1076